Funding withdrawn from University Hospital Southampton NHS Trust conducting COVID-19 ACCORD clinical study of AXL kinase inhibitor bemcentinib

Following decision to cease funding for the study, in which bemcentinib was the lead drug candidate, due to reduced incidence of COVID-19 in UK, the company Bergenbio is in process of conducting a similar study in a country of high COVID-19 incidence.


Biospace Inc.